Global Glioblastoma Multiforme Treatment Market - Industry Trends and Forecast to 2029

Segmentation

Short Description Global Glioblastoma Multiforme Treatment Market, By Type (Primary (De Novo), Secondary), Treatment (Surgery, Radiotherapy, Medications), Patient Type (Adult, Geriatric, Child), Drug Type (Generics, Branded), Route of Administratin (Parenteral, Oral, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Israel, UAE, Rest of Middle East and Africa) Industry Trends and Forecast to 2029 Market Definition: Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor and accounts for 60% of brain tumors in adults. GBMs can arise in the brain de novo or evolve from lower-grade astrocytoma. In adults, GBM occurs most often in the cerebral hemispheres, especially in the frontal and temporal lobes of the brain. Many genetic and environmental factors have been studied in glioblastoma multiforme, but no risk factor that accounts for a large proportion of GBM has been identified. So like many other cancers, GBM is sporadic, although some studies indicate a high prevalence (17%) of prior therapeutic irradiation among patients with GBM. The latency between irradiation and the development of GBM varies from a few years to several decades. There is no substantial evidence of GBM association with lifestyle factors like smoking, alcohol consumption, drug use, or exposure to N- Nitroso compounds. Studies have shown that the use of mobile phones doesn't increase the risk of development of GBM; however, its association with long term use needs further confirmation Market Segmentation: The glioblastoma multiforme treatment market is categorized into seven notable segments based on type, treatment, patient type, drug type, route of administration, end user and distribution channel. On the basis of disease type, the glioblastoma multiforme treatment market is segmented into primary (De Novo) and secondary On the basis of treatment, the glioblastoma multiforme treatment market is segmented into surgery, radiotherapy and medications On the basis of patient type, the glioblastoma multiforme treatment market is segmented into adult, geriatric and child On the basis of drug type, the glioblastoma multiforme treatment market is segmented into generics and branded On the basis of route of administration, the glioblastoma multiforme treatment market is segmented into parenteral, oral and others On the basis of end user, the glioblastoma multiforme treatment market is segmented into hospitals, clinics, home healthcare and others On the basis of distribution channel, the glioblastoma multiforme treatment market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others Market Players Some of the major players operating in the market are: F. Hoffmann-La Roche AG Amgen Inc. Merck & Co., Inc. Pfizer Inc. Varian Medical Systems, Inc. (A subsidiary of Siemens Healthcare) ZEISS International Amneal Pharmaceuticals LLC Elekta Sun Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd. Eckert & Ziegler Accord Healthcare Angiochem ANI Pharmaceuticals, Inc. Arbor Pharmaceuticals, LLC. (A Subsidiary of Azurity Pharmaceuticals, Inc.) AstraZeneca Cantex Pharmaceuticals, Inc. CELON LABS Diffusion Pharmaceuticals Inc. EnGeneIC ERC.SA. Genenta science Jazz Pharmaceuticals, Inc. Loxo Oncology (A Subsidiary of Eli Lilly) Novartis AG VBL THERAPEUTICS Viatris Inc. Zydus Pharmaceuticals, Inc.,

Methodology